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Abstract
Pediatric-onset ataxias often present clinically with developmental delay and intellectual 
disability, with prominent cerebellar atrophy as a key neuroradiographic finding. Here we describe 
a novel clinically distinguishable recessive syndrome in 12 families with cerebellar atrophy 
together with ataxia, coarsened facial features and intellectual disability, due to truncating 
mutations in sorting nexin 14 (SNX14), encoding a ubiquitously expressed modular PX-domain-
containing sorting factor. We found SNX14 localized to lysosomes, and associated with 
phosphatidyl-inositol (3,5)P2, a key component of late endosomes/lysosomes. Patient cells 
showed engorged lysosomes and slower autophagosome clearance rate upon starvation induction. 
Akizu et al. Page 2
Nat Genet. Author manuscript; available in PMC 2015 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Zebrafish morphants showed dramatic loss of cerebellar parenchyma, accumulated 
autophagosomes, and activation of apoptosis. Our results suggest a unique ataxia syndrome due to 
biallelic SNX14 mutations, leading to lysosome-autophagosome dysfunction.
The hereditary cerebellar ataxias are a group of clinical conditions presenting with 
imbalance, poor coordination, and atrophy/hypoplasia of the cerebellum, most often with 
deterioration of neurological function. A common hallmark of cerebellar ataxias is a 
progressive cerebellar neurodegeneration due to Purkinje cell loss. A combination of 
dominant, recessive and X-linked forms of disease, including the spinocerebellar ataxias, 
Friedreich ataxia, and ataxia telangectasia contribute to the estimated prevalence of 8.9 per 
100,0001. In addition to the dominant trinucleotide repeat disorders that lead to toxic 
accumulation of unfolded protein2, 3, the recessive forms of disease are associated with 
inactivating mutations and early-onset presentations. The genes implicated to date suggest 
defects in neuronal survival pathways4, 5, but many mechanisms are still lacking and most 
patients elude genetic diagnosis.
Recessive ataxias often show clinical overlap with lysosomal disorders, and in fact, many 
lysosomal diseases such as Niemann-Pick, Tay-Sachs, and I-cell disease show evidence of 
Purkinje cell loss and clinical features of ataxia, in addition to the well established features 
of enlarged organs and coarsening of facial features6–8. These overlaps suggest that 
cerebellar cells are exquisitely sensitive to otherwise generalized perturbations of lysosomal 
function.
Autophagy is the major pathway for intracellular catabolic degradation of most long-lived 
proteins and organelles, thus providing nutrients during starvation9. When core components 
are impaired, the result is multisystem organ involvement that includes 
neurodegeneration9–13. In the major pathway, termed macroautophagy, the autophagosome 
fuses with multivesicular body (MVB) or the lysosome, and the contents are degraded via 
acidic hydrolases. The fusion events are at least partially regulated by the phosphatidyl-
inositol (PI) lipid components of the respective membranes, with PI(3)P associated with 
autophagosomes and PI(3,5)P2 associated with MVBs and lysosomes14. Yet the proteins 
regulating these relatively late-stage fusion events are mostly unknown.
We studied a cohort of 96 families presenting with likely autosomal childhood-onset 
recessive cerebellar atrophy with ataxia, 81 of which had a history of parental consanguinity, 
and 76 of which had two or more affected members without congenital malformations or 
environmental risk factors. We performed whole exome sequencing (WES) on at least one 
member of each of the families, according to published protocols15. For families with 
documented consanguinity, we prioritized homozygous, rare (<0.2% allele frequency in our 
in-house exome database of 3000 individuals) and potentially damaging variants (Genomic 
Evolutionary Rate Profile (GERP) score >4 or phastCons (genome conservation) >0.9). 
Many of the families displayed damaging mutations in genes already implicated in 
cerebellar atrophy, including NPC1, and GRID2. Overall, 15% of cases showed mutations in 
genes that fully explained their presentation (Supplementary Table 1), 60% of families 
showed no obvious candidates, and 25% displayed putative mutation in a gene or genes not 
previously implicated in human disease (Fig. 1a).
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To identify causative mutations, we focused on Family 468, with three similarly affected 
and one healthy child, which allowed for parametric linkage analysis, defining a single 
major locus between chr6:55153677-91988281 (hg19) (LOD = 2.528) (Supplementary Fig. 
1). Alignment of all LOD > -2 loci with WES from two affecteds highlighted a single c.
1132C>T variant in the SNX14 gene predicting a p.Arg378*. Turning our attention to this 
gene from the remaining WESed patients, we identified a total of 16 patients from 8 families 
with truncating variants throughout the coding region, nearly all in constitutively spliced 
exons, and predicted as loss of function (Fig. 1b-d, Supplementary Fig. 2, Supplementary 
Table 2). All patients displayed a block of homozygosity on chromosome 6, containing the 
SNX14 gene (Supplementary Fig. 1) and mutations segregated according to a recessive mode 
of inheritance. Variants in other genes in these patients were either previously described 
SNPs in other populations or were of unknown significance (Supplementary Table 3). Three 
families shared the same p.Arg378* mutation and analysis confirmed a common 1.5 mb 
haplotype, supportive of a founder mutation (Supplementary Fig. 1). Overall, patients with 
SNX14 variants accounted for 10% of families, making it the single most commonly mutated 
gene in our cohort. Furthermore, while preparing this manuscript, WES from an additional 
consanguineous family with 4 children with cerebellar atrophy independently identified a 
homozygous truncating mutation in SNX14 (Supplementary Fig. 2).
SNX14 encodes 946 amino acids, and contains two transmembrane domains, a regulator of 
G protein signaling (RGS) domain, predicted to act as a GTPase activating protein (GAP) 
and a phox homology (PX) domain predicted to bind phosphoinositide lipids and function in 
intracellular trafficking. Alternate splicing results in transcript variants encoding distinct 
isoforms. Patient SNX14 variants predicted both early and late truncating events, suggesting 
loss of function as the disease mechanism (Fig. 1c-d).
Patients showed several common features in addition to the age-dependent atrophy of the 
cerebellum, with evidence of cerebral cortical atrophy in about half (Table 1 and 
Supplementary Table 4). One deceased patient studied neuropathologically showed near 
absence of Purkinje cells. The few Purkinje cells remaining were ectopically located and 
atrophic with enlarged apical neurites. Bergmann gliosis was prominent in the depopulated 
Purkinje cell layer and neurofilament immunostaining revealed radially oriented bundles of 
distended axons located on the superficial part of the internal granule layer. Forebrain also 
presented neuronal loss although less severe than in the cerebellum (Fig. 1e, Supplementary 
Fig. 3).
Most patients presented between birth and 1 year of age with global developmental delay 
and hypotonia. Seizures developed in half by 2 years, and were well controlled with 
anticonvulsant medication. Nystagmus, difficulty ambulating and reduced deep tendon 
reflexes were seen in most children, and sensorineural hearing loss was seen in about one 
third. Coarsened facial features with prominent forehead, epicanthal folds, upturned nares, 
long philtrum, and full lips were seen in all, features approximating mucopolysaccharidosis 
or other lysosomal storage disorders (LSDs) (Fig. 1b and Supplementary Fig. 2b). Likewise, 
ultrastructural analysis of spinal cord tissue found axonal spheroids filled with membranous 
structures reminiscent of cytoplasmic membranous bodies in LSDs16 (Supplementary Fig. 
3c). Palpable liver or spleen edge was detected in 5 of 18 patients, but no evidence of 
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abnormal liver, urine or hematological chemistries were apparent. Urine oligosaccharides 
showed an abnormal pattern in one affected, and two patients showed elevated urinary 
glycosoaminoglycans. However detailed lysosomal enzyme analysis in plasma and 
leukocytes from two affected members proved unremarkable (Supplemental Note). 
Although initially WES was required to identify patients, as the clinical presentation 
clarified, we were able to predict mutations with 100% certainty, identifying an additional 4 
patients from 3 families with homozygous SNX14 mutations, suggesting a, heretofore 
unknown, clinically recognizable condition (Fig. 1, Supplementary Fig. 2 and Table 2).
SNX14 mRNA showed nearly uniformly even expression in human fetal and adult tissue 
(Fig. 2a). Cellular fractionation aimed to distinguish the major membrane-bound pools in 
wildtype human neural precursor cells identified SNX14 predominantly associated with a 
lysosomal rich fraction (Fig. 2b). Tagged SNX14 overexpression confirmed overlapping 
localization with lysosomes (Fig. 2c, Supplementary Fig. 4), but not with other endosomal 
or Golgi markers that were present in the SNX14 fraction, suggesting a role in lysosomal 
function. Furthermore, lipid binding assay with the recombinant PX domain from SNX14 
showed specific albeit relatively weak direct binding with PI(3,5)P2, the predominant 
phosphoinositide (PI) associated with lysosomes (Fig. 2d).
To identify lysosomal defects associated with SNX14 mutations, we generated induced 
pluripotent stem cells (IPSCs) and then differentiated neural precursor cells (NPCs) through 
reprograming of SNX14 patients and control fibroblasts from families 468 and 138217, 18. 
Like the patient fibroblasts, SNX14 protein was absent from patient NPCs (Fig. 3a and 
Supplementary Fig. 5). While we noted no difference in reprogramming, differentiation or 
cellular survival in culture (Supplementary Fig. 5), lysosomes appeared increased in size in 
patient NPCs (Fig. 3b, Supplementary Fig. 6). To quantitate this effect, we performed flow 
cytometric analysis to gate for fluorescent signal upon Lysotracker labeling, and found about 
twice the number of patient cells falling outside of the normalized intensity distribution 
(Supplementary Fig. 6a).
In order to assess if this lysosomal enlargement affected lysosomal activity, we tested NPCs 
for active Cathepsin D (which depends upon both lysosomal localization of the enzyme and 
acidification), using Bodipy FL Pepstatin A19 and found no obvious differences in intensity 
of stained lysosomes (Supplementary Fig. S6d). However immunoblot analysis detected 
slight but significant reduction in Cathepsin D levels in affected compared to unaffected 
NPCs (Supplementary Fig. 7c), suggesting that a fraction of lysosomes may be defective for 
Cathepsin D. Although defects in other lysosomal enzyme activities were not tested in 
NPCs, our findings are reminiscent of lysosomal storage disorders (LSDs).
Autophagy requires fusion of lysosomes with autophagosomes, so lysosomal abnormalities 
could result in autophagic defects such as those observed in LSDs6–8. In order to test for 
potential autophagic defects, patient NPCs were cultured under starvation conditions, then 
assessed for lipidated LC3 (i.e. LC3 II) levels, which marks autophagosomes. While all lines 
showed increased LC3 II levels upon serum starvation, patient cells showed a more dramatic 
response, which was reproduced by an alternative induction of autophagy through mTOR 
pathway inhibition with rapamycin. Importantly, the increased LC3 II levels were recovered 
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to basal rates by forced expression of tagged SNX14 into patient cells (Fig. 4a). By LC3 flux 
analysis in nutrient deprived conditions, where LC3II ratios in the presence and absence of 
lysosomal inhibitors (Leupeptin and NH4Cl) were calculated20, we identified slower LC3 
flux in patient cells compared to controls. This, together with no differences observed in 
autophagosome formation (assessed as the increase in LC3-II levels at two time points after 
inhibition of lysosomal proteolysis, Fig. 4b), suggests that SNX14 mutant neural progenitors 
are defective in autophagosome clearance. To confirm, we performed electron microscopy 
and found that patient cells show autophagosome accumulation (Fig. 4c), consistent with 
disrupted autophagosome clearance.
We thus repeated the cell fractionation analysis upon serum starvation to induce autophagy, 
and observed SNX14 enriched in the most heavily LC3-lipidated fractions (Supplementary 
Fig. 7a). Furthermore, upon serum starvation, SNX14 showed overlapping 
immunofluorescence localization with LC3 (Supplementary Fig. 7b), suggesting at least 
some fraction of SNX14 associates with autophagic structures, consistent with a role in 
autophagosome clearance.
In order to demonstrate the role of SNX14 in cerebellar function, we established an in vivo 
zebrafish model, where we found a single snx14 ortholog (NM_001044793), with strong 
neural expression (Supplementary Fig. 8). Injection of a specific snx14 translation blocking 
morpholino resulted in loss of neural tissue volume (Fig. 5a). Immunostaining of these 
embryos for Zebrin II, an early Purkinje cell marker, showed significantly reduced cellular 
area, an effect that was quantifiably rescued by co-injection with the human SNX14 ortholog 
(Fig. 5b). Morpholino injection into the Tg(ptf1a:EGFP) zebrafish line, which expresses 
GFP in the hindbrain21, confirmed overall reduction in GFP intensity (Fig. 5c) and 
suggested SNX14 is required for hindbrain and Purkinje cell generation or survival. To 
distinguish between these possibilities, we performed staining for activated caspase 3, and 
found a dramatic increase in signal throughout the assessed neural tissue. Transmission 
electron microscopy analysis of neural cells demonstrated accumulation of autophagic 
structures in snx14 morphants. These data suggests that SNX14 mutations leads to neuronal 
cell death associated with impaired autophagic degradation.
In summary, we have characterized a cerebellar ataxia syndrome (SCAR17), caused by null 
mutations in SNX14. Our paper adds to the recent report of cerebellar atrophy with 
intellectual disability and coarse facies also showing homozygous SNX14 mutations22. Our 
work, with the addition of a larger cohort, helps identify clinical features that are variable, 
such as camptodactyly, macrocephaly, and epilepsy and delineate the common pathology 
clearly distinguishable from other ataxias confirming this as a novel syndrome as 
suggested23.
Our study identifies the association of SNX14 with autophagy and neurodegeneration. 
Currently, of the 30 or so SNX genes in humans, only SNX10 is linked to human Mendelian 
disease, with a homozygous mutation in a single family with malignant infantile 
osteopetrosis24. Other SNX proteins are suggested to play roles in synaptic function25, 26, 
and neuronal survival especially relevant in Alzheimer’s disease27–30 through their function 
in cargo sorting, but SNX14 is the first to be genetically implicated. We propose a role for 
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SNX14 mediating fusion of lysosomes with autophagosomes, an area of intense research, 
and through manipulation of autophagy, may provide a promising therapeutic target 
currently under investigation for other degenerative conditions31.
ONLINE METHODS
Patient Ascertainment
Patients were enrolled and sampled according to standard local practice in approved human 
subject protocols at the University of California. Patients were recruited from developmental 
child neurology clinics throughout the Middle East, North Africa and Central Asia 
presenting with features of neurodevelopmental delay or regression, ataxia, intellectual 
disability, autism, epilepsy or structural brain malformations between 2004 and 2012. 
Recruitment was focused in the major population centers of the Middle East including 
Morocco, Libya, Egypt, Saudi Arabia, Kuwait, UAE, Oman, Jordan, Pakistan, Turkey and 
Iran, with consanguinity rates (i.e. rate of marriage between first or second cousins) of 
approximately 50% compared with <1% is US and Western Europe. Among the recruited 
cohort, consanguinity was present in 63% of parents, suggesting some bias in sampling 
towards those with affected children due to recessive disease. Sampling was performed on 
both parents and all available genetically informative siblings to include affected and 
unaffected members, as well as extended family members if appropriate, upon informed 
consent approval and consistent with IRB guidelines. General and neurological examination, 
clinical records, radiographs, photographs, videos documenting movement, and past history 
were reviewed and patients were examined by one or more of the authors. Analysis of all 
patients presenting with a presumptive diagnosis of Cerebellar Atrophy were included in the 
analysis, based upon the finding of reduced cerebellar volume, and excessively prominent 
interfolial spaces on axial or sagittal sections. Patients with MRI showing pronounced 
pontine atrophy, severe peripheral neuropathy, white matter disease, telangiectasias, retinal 
blindness, or major cortical malformations such as cobblestone lissencephaly, were 
excluded. Patients with evidence of mitochondrial disease, abnormal transferrin isoelectric 
focusing, lysosomal storage such as mucolipidosis or ceroid were excluded. All patients 
were excluded for the common Friedreich ataxia expansion, and tested normal for alpha-
fetoprotein and albumin. Blood and/or saliva was collected on all consenting potentially 
informative family members, DNA extracted with the Qiagen AutoPure instrument, and 
subject to quality control measures to measure concentration/purity and to confirm 
inheritance, and subject to subsequent genetic investigation.
Whole exome sequencing
WES was performed on two affected members per family when available, or both parents 
and affected member from singleton cases. Genomic DNA was subject to Agilent Human 
All Exon 50Mb kit library preparation, then paired-end sequencing (2x150bp) on Illumina 
HiSeq 2000 instrument. For each patient sample, >96% of the exome was covered at >12x. 
GATK1 was used for variant identification. We tested for segregating rare structural variants 
using XHMM2. We then prioritized homozygous variants using custom Python scripts 
(available upon request), to remove alleles with >0.1% frequency in the sequenced 
population, not occurring in homozygous intervals at least 2 cM in size or linkage intervals 
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with more than -2 LOD score, or without high scores for likely damage to protein function. 
All variants were prioritized by allele frequency in publically available databases, 
conservation, and predicted effect on protein function, and were tested for segregation with 
disease.
Sanger sequencing
Primers were designed using the Primer3 program and tested for specificity using NIH 
BLAST software. PCR products were treated with Exonuclease I (Fermentas) and Shrimp 
Alkaline Phosphatase (USB Corporation) and sequenced using BigDye terminator cycle 
sequencing Kit v.3.1 on an ABI 3100 DNA analyzer (Applied Biosystems). Sequence data 
was analyzed by Sequencher 4.9 (Gene Codes) to test segregation of the mutation with the 
disorder under a recessive mode of inheritance, taking advantage of all informative meioses 
in each family.
Cloning of human SNX14
The human SNX14 from adult brain cDNA was amplified and cloned into pdsRED2-C1 
vector, and subcloned into doxycycline inducible lentiviral pINDUCER20 vector3. For N 
terminal Flag, SNX14 was amplified from adult brain cDNA using a 5’ primer containing 
Flag sequence and cloned into pINDUCER20 vector. SNX14 PX domain was amplified and 
cloned into pGEX-6P-1 vector for purified protein expression.
Human brain histology, oligosaccharide and glycosaminoglycan measurement
Sections were deparaffinized, and stained with 0.1% Luxol fast blue, 0.1% Cresyl violet or 
hematoxylin-eosin. Immunohistochemistry was performed with primary dilution of 1:200 
antibody (Calbindin ABCAM ab11426, Neurofilament Pierce MIC-N18) and visualized 
with secondary HRP antibody (Jackson Labs). Control tissue corresponds to biobank 
identification number BB-0033-00082. Oligosaccharide and glycosaminoglycan 
measurements were performed as described4.
Fibroblast, IPSC and Neural Progenitor Cell culture
Fibroblasts were generated from explants of dermal biopsies collected from affected and 
unaffected volunteers, previously genotyped, and cultured in MEM (Gibco)/20% FBS 
(Gemini). IPSCs were generated as previously described from5. Briefly, three micrograms of 
expression plasmid mixtures (OCT3/4, SOX2, KLF4, L-MYC, LIN28 and p53 shRNA) 
were electroporated into 6X105 of cell, trypsinized 7d afterwards, and 1.5X105 cells were 
re-plated onto 100-mm dishes with 1.5X105 irradiated CF-1 mouse embryonic fibroblasts 
(MEF) feeder layer. The culture medium was replaced the next day with standard hESC/
IPSC medium, DMEM:F12 supplemented with 20% KOSR and 20 ng/ml bFGF (Invitrogen) 
1X nonessential amino acids, 110 µM 2-Mercaptoethanol. Colonies were selected for further 
cultivation and evaluation. After 3 passages IPSCs cells were transferred to MEFs free 
plates and growth in mTeSr medium (Stem Cells Technologies). Neural progenitors cells 
(NPCs) were obtained as previously described6. Briefly, embryoid bodies (EBs) were 
formed by mechanical dissociation of cell clusters and plated in suspension in differentiation 
medium (DMEM F12, 1X N2, 1µM Dorsomorphin (Tocris), 2 µM A8301 (Tocris)) and kept 
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shaking at 95 rpm for 7 days. Resultant EBs were plated onto Matrigel (BD Biosciences) 
coated dishes in NBF medium (DMEM F12, 0.5X N2, 0.5X B27, 20ng/ul bFGF). Rosettes 
were collected after 5–7 days, dissociated with Accutase (Millipore), and resultant NPCs 
plated onto poly-ornithine/laminin (Sigma) dishes with NPC medium. Medium was replaced 
every 2 days. Cells were routinely tested for mycoplasma. All experiments were performed 
with NPCs at passage 5–8.
For the genetic replacement experiments, patient NPCs were transduced with lentivirus 
containing Flag or dsRED tagged SNX14 (NM_153816) in pINDUCER20 vector3 in the 
presence of 8 µg/mL polybrene. Following one-week selection with 200 µg/ml G418, NPCs 
were treated with 50 ng/ml doxycyline for the transgene expression. Bright field images 
were taken in Olympus IX51 inverted microscope or in EVO microscope and processed with 
Photoshop CS5 (Adobe Systems). For autophagic induction cells were cultured in EBSS 
(Earl’s balanced salt solution) for 1.5–2 hr and treated with Leupeptin 200 µM and NH4Cl 
20 mM for experiments performed to quantify LC3 II flux and autophagosome formation.
Cell fractionation assay
Cell fractionation was carried out as described previously7. Proteins in each fraction were 
precipitated with methanol-chloroform and resuspended in 60 µl of protein loading buffer 
from which 20 µl was processed for immunoblot analysis.
Lipid binding assay
The lipid blots were performed essentially as described previously8 with minor 
modifications. Briefly, 180, 60 and 20 pmol lipids were spotted on PVDF membranes and 
probed with 0.75ug of bacterially expressed GST-tagged PX domains. Proteins were 
detected by blotting with an anti-GST antibody.
Cellular Immunofluorescence and biochemical assays
Cells were fixed in 4% PFA for 10 min, permeabilized with 0.05% Triton in PBS or 
methanol, blocked for 1 hr in PBS containing 0.05% and 2% donkey serum, then incubated 
with primary antibody (LC3, 1:200, Cell Signaling (2775), Lamp1, 1:200, DSHB (H4A3), 
Lamp2, 1:200, Abcam (Ab25631), EEA1, 1:200, BD (610456), GM130 1:200, Cell 
Signaling (2296)), overnight at 4°C, washed, and incubated with fluorescent secondary 
antibodies (Jackson ImmunoResearch) for 2 hr. Imaging was on an Olympus IX51, Leica 
SP5, or Nikon A2, processed with Photoshop CS5 (Adobe Systems). Cathepsin D activity 
was assessed with 2µg/ml Bodipy FL Pepstatin A for 45 min at 37°C, then fixed in 4% PFA 
before imaging.
For immunoblot assays fibroblasts or NPCs were lysed with ice-cold RIPA buffer 
supplemented with protease and phosphatase inhibitor cocktails (Roche). Proteins were 
separated in 10% SDS-PAGE gels and transferred to PVDF membrane, blocked with 5% 
milk in 1x TBS-T, and blotted with primary antibody (mouse anti-SNX14, 1:1000, Sigma 
(SAB1304492), rabbit anti-LC3, 1:5000, Novus Biological (NB600-1384), mouse anti-
Tubulin, 1:1000, Sigma (T6074), mouse anti-GAPDH, 1:1000, Millipore (MAB347), anti-
Ribophorin, 1:1000, Abcam (ab38451), p62, 1:1000 Progen Biotechnik (GP62-C), 
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Cathepsin D, 1:1000, Santa Cruz (C20), EEA1, 1:500, BD (610456), Lamp1, 1:500, DSHB 
(H4A3), GM130 1:500, Cell Signaling (2296)) overnight at 4°C. Detection used a 
peroxidase-coupled anti-IgG antibody (Pierce) and an enhanced chemiluminescence 
substrate (Thermo Scientific Pierce ECL). Experiments were replicated three times.
For RT-PCR, total RNA was extracted with RNeasy Mini Kit (Qiagen), a total of 2 µg RNA 
was transcribed to cDNA using the SuperScript (Invitrogen) with oligodT. Specific primers 
were used for PCR.
Flow cytometry for Lysotracker intensity analysis
Neural progenitor cells were harvested, brought to 10x5 cells/ml and incubated with 100 nM 
Lysotracker Green DND-26 for 15 min at 37°C. Live cells were analyzed for Lysotracker 
fluorescence intensity levels by first gating on all cell material except small debris in the 
origin of a FSC versus SSC dot-plot. Lysotracker signal from samples were then compared 
by dot plot and histogram analysis.
Zebrafish In situ hybridization, knockdown and immunofluorescence
Adult male and female zebrafish (<18 months old) from wild-type (AB Tübingen) and 
transgenic strains were maintained under standard laboratory conditions. At least three adult 
pairs were used to generate embryos at 0–5 d.p.f. for each experiment, with embryos from 
the same pair used both for control and snx14 morpholino injections. No randomization was 
performed. Translational blocking antisense morpholino oligonucleotides (MO) for snx14 or 
scrambled sequence MO were injected into one-cell stage embryos. Full-length human wild-
type SNX14 mRNA (50 ng) was co-injected with the MO as described9. Optic tectum and 
right eye width was measured digitally to assess neural affectation. Whole-mount in situ 
hybridization was performed on 24 and 48 hours post fertilization (hpf) zebrafish embryos 
using snx14 RNA probes generated by PCR. Experiments followed NIH guidelines and were 
performed in compliance with IACUC at University of California San Diego.
Transmission electron microscopy
Samples were immersed in modified Karnovsky’s fixative (2.5% glutaraldehyde and 2% 
paraformaldehyde in 0.15 M sodium cacodylate buffer, pH 7.4) for at least 4 hours, 
postfixed in 1% osmium tetroxide in 0.15 M cacodylate buffer for 1 hour and stained en bloc 
in 2% uranyl acetate for 1 hour. Samples were dehydrated in ethanol, embedded in 
Durcupan epoxy resin (Sigma-Aldrich), sectioned at 50 to 60 nm on a Leica UCT 
ultramicrotome, and picked up on Formvar and carbon-coated copper grids. Sections were 
stained with 2% uranyl acetate for 5 min and Sato's lead stain for 1 min. Grids were viewed 
using a Tecnai G2 Spirit BioTWIN transmission electron microscope equipped with an 
Eagle 4k HS digital camera (FEI).
Statistical analysis
All experiments were replicated at least twice. Data are expressed as means with variance as 
s.e.m. or s.d. For all quantitative measurements a normal distribution was assumed and we 
used the two-tailed Student t-test to perform between group comparisons. p-value <0.05 was 
considered indicative of statistical significance. No statistical methods were used to 
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predetermine sample sizes, which were determined empirically from previous experimental 
experience with similar assays and/or from sizes generally employed in the field. Data 
collection and analysis were not performed with blinding. Raw values used to generate plots 
is available as source data.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. SNX14 mutations cause a syndromic form of severe cerebellar atrophy and coarsened 
facial features
(a) Summary of exome results from 81 families with cerebellar atrophy. SNX14 accounted 
for 9.88% of the total families, with other genes making individual contributions. (b) 
Midline sagittal (top) or axial (middle) MRI and facies of affected individuals from 
representative families. Prominent atrophy of cerebellum evidenced by reduced volume and 
apparent folia (arrows and circles). Facies show prominent forehead, epicanthal folds, long 
philtrum and full lips. Consent to publish images of the subject was obtained. (c) SNX14 
exons as ticks and location of mutations indicated. Scale bar 50 kb. (d) Truncating mutations 
relative to predicted protein domains. TM: Transmembrane, PXA: Phox homology 
associated, RGS: Regulator of G protein signaling, PX: Phox homology, PXC: Sorting 
Nexin, C-terminal. (e) ABD-II-2 (p.Arg378*) hematoxylin-eosin stained cerebellum 
compared with control showing reduction in internal granule cell layer (arrow, top), near 
complete depletion of Purkinje cells (arrow, middle), and dystrophic degenerating remnant 
Purkinje cell (arrow, bottom). Scale bar 100 µm.
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Figure 2. SNX14 localizes to late endosome/lysosome compartments
(a) RT-PCR expression pattern of human SNX14 showing ubiquitous expression in 
representative fetal and adult human tissues. GAPDH: loading control. (b) Cell fractionation 
from human neural progenitor cells (NPCs). SNX14 was enriched in lysosomal-endosomal 
compartments (red). (c) LAMP2, EEA1 and GM130 (green) in dsRED tagged SNX14 
expressing NPCs. SNX14 overlapped in localization with LAMP2 lysosomal marker 
(arrows). Scale bar 10 µm. (d) Lipid binding assay with SNX14 PX domain on 
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phosphoinositides-spotted membrane, showed preferential binding to PI(3,5)P2 (red), 
compared with p40phox PX domain control.
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Figure 3. Patient-derived SNX14 mutant neural progenitor cells display enlarged lysosomes
(a) Immunoblot of IPSC-derived neural progenitor cells (NPCs) from families 468 
(p.Arg378*) and 1382 (p.Lys395Argfs*22), with affected (A, red) and unaffected (U, black) 
labeled. Affecteds showed undetectable SNX14 protein. GAPDH: loading control. (b) 
Lysotracker Green DND-26 staining with engorged lysosomes in affecteds NPCs (arrows). 
Scale bar 5 um. Dot plot shows relative area for individual LysoTracker positive lysosomes 
(n = 223 and 194 lysosomes from 2 families unaffected and affected NPCs respectively, N = 
2). Graph bars represent average number of LysoTracker-positive lysosomes per cell (n = 17 
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and 18 from 2 families unaffected and affected NPCs respectively, N = 2). Error bars, S.D. 
*** p < 0.0005, N.S. not significant (two tiled t-test).
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Figure 4. Patient-derived SNX14 mutant neural progenitor cells display abnormal starvation-
induced autophagic response
(a) Immunoblot analysis of LC3 II in affected (red), unaffected and affected transduced with 
SNX14 (grey) NPCs upon induction of autophagy by starvation with 1 hr 30 min EBSS 
(Eagle’s Balanced Salt Solution) or rapamycin (1 µM for 2 hr). Graph bars represent average 
LC3II/αTubulin levels relative to feeding condition. Error bars S.D. (N = 3 clones) * p < 
0.05, ** p < 0.005, N.S. not significant (two tiled t-test). Affected cells display an 
accumulation of LC3 II levels upon autophagic induction, partially rescued by exogenous 
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SNX14 expression. (b) LC3 immunoblot (left) for quantification of autophagic flux 
measured by LC3 II ratio in lane 3 vs. lane 2 for unaffected and lane 7 vs. lane 6 for affected 
(red) (middle), and quantification of autophagosome formation (left) assessed as the increase 
in LC3-II levels at two time points (lane 4 vs. lane 3 for control, and lane 8 vs. lane 7 for 
affected) after inhibition of lysosomal proteolysis with Leupeptin 200 µM and NH4Cl 20 
mM (PI 30 min/PI 1 hr). Graph represent mean ± S.D. (N = 3 clones) * p < 0.05, N.S. not 
significant (two tailed t-test) (c) Transmission electron microscopic analysis of 2 hr EBSS 
treated unaffected (black) and affected (red) NPCs showing autophagic structures in 
affecteds (arrowheads). Data represents results from one NPC clones from each affected or 
unaffected.
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Figure 5. Morphant snx14 zebrafish show apoptosis, excessive autophagic vesicles, and loss of 
neural tissue including cerebellar primordium
(a) Comparison of scrambled (6ng) and snx14 (3ng and 6ng) morphant zebrafish 48 hours 
postfertilization (hpf). Calipers: measured distance. Scale bar 250 µm. Graphs: Reduced 
optic tectum and right eye width in morphants. Mean ± SEM (n = 15 embryos for NI, 16 for 
Scramble, 31 for MO 3ng and 18 for MO 6ng, N = 2). *p < 0.05; **p < 0.005 (two tiled t-
test). (b) Scramble or snx14 morphants for Zebrin II (Purkinje cell marker), rescued with 
human SNX14 (50 pg). Scale bar 50 µm. Graph: Zebrin II compartment area relative to 
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scramble MO injected embryos. Mean ±SEM (n = 10 embryos for Scramble, 6 for MO 3ng, 
9 for MO 6ng and 9 for rescue) *p < 0.05; **p < 0.005 (two tiled t-test). (c) Maximum 
confocal projection from 36 hpf Tg(ptf1a:eGFP) (green) zebrafish with scramble or snx14 
MO showing reduced Purkinje cell progenitors. (d) Maximum confocal projection with 
increased caspase 3 (red) positive cells in 36 hpf snx14 morphants. Blue: DAPI. Scale bar 50 
µm. (e) Transmission electron microscopy showing autophagic structures in 48 hpf snx14 
and scrambled morphant neurons residing between the optic lobes. Box: Highlighted areas. 
Arrowheads: autophagic structures.
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Table 1
Clinical findings in SNX14 mutated individuals. (See Supplemental Table 4 for detailed clinical information).
Development Percent of patients displaying feature
Delayed gross motor 22/22
Delayed fine motor 22/22
Delayed or absent language 22/22
Delayed or absent social 22/22
Autistic-like behavior 12/22
Neurological Findings
Epileptic Seizures 8/22
Hypotonia 22/22
Nystagmus 11/22
Gait wide based or absent 22/22
Cerebellar atrophy on brain MRI 22/22
Storage disorder phenotype
Coarse facies 22/22
Hearing loss (SNHL) 5/22
Kyphoscoliosis, clinodactyly 10/22
Hepatosplenomegaly 5/22
Hypertrichosis 12/22
Macroglossia 12/22
Atrial septal defect or patent ductus 2/22
Urine oligosaccharides or glycosylaminoglycans 5/22
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